Chief Scientific Officer · Compass Therapeutics, Inc. (CMPX)

Susan Kalled

FY2021 is the first fiscal year CompBrief holds for Susan Kalled as a named executive officer of Compass Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,781,616

Salary $220,000Stock awards $0Bonus $115,500

3rd of 3 named executive officers at Compass Therapeutics by FY2021 total.

3 named officers on file for Compass Therapeutics, FY2021

Susan Kalled’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Compass Therapeutics’s whole pay program stands against its peers

  • Compass Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CMPX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Susan Kalled’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Susan Kalled compensation by year

Compass Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Compass Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$220,000
Bonus$115,500
Stock awards$0
Option awards$1,446,116
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$1,781,616

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Compass Therapeutics, Inc. DEF 14A filed April 28, 2022, accession 0001140361-22-016447, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Compass Therapeutics, Inc. filed document, accession 0001140361-22-016447. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option260,000—$7.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Compass Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Compass Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Thomas SchuetzChief Executive Officer$5,258,000
Vered Bisker-LeibPresident and Chief Operating Officer$4,450,000
Susan Kalled · this pageChief Scientific Officer$1,781,616

The full Compass Therapeutics compensation record

free company brief

This page is one person within Compass Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Compass Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Susan Kalled's compensation dossier · One-time report. No refunds.